Sorry, you need to enable JavaScript to visit this website.

METHOTREXATE (methotrexate) Contraindications

Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click here to learn how we are responding.
Pfizer reconnaît les préoccupations du grand public concernant la situation liée à la COVID-19, qui continue d'évoluer. Cliquez ici pour savoir comment nous avons réagi.


Methotrexate Injection USP is contraindicated:

  • In patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section.
  • In patients with severe renal impairment.
  • In pregnant patients with psoriasis or rheumatoid arthritis and should be used in the treatment of neoplastic diseases only when the potential benefit outweighs the risk to the fetus.
  • In women of childbearing potential until pregnancy is excluded.
  • In nursing mothers.
  • In patients with psoriasis or rheumatoid arthritis with alcoholism, alcoholic liver disease or other chronic liver disease.
  • In patients with psoriasis or rheumatoid arthritis who have overt or laboratory evidence of immunodeficiency syndromes.
  • In patients with psoriasis or rheumatoid arthritis who have pre-existing blood dyscrasias, such as bone marrow hypoplasia, leucopenia, thrombocytopenia or significant anemia.
  • With nitrous oxide anesthesia (see WARNINGS AND PRECAUTIONS: Renal and DRUG INTERACTIONS: Drug-Drug Interactions).

Methotrexate Injection USP formulations containing benzyl alcohol are also contraindicated:

  • To use for intrathecal, intraventricular, or high-dose therapy.
  • To use in neonates (children less than one month age).

What's New

No Current Announcements.

Contact Pfizer Medical Information

Report an Adverse Event
1 866 723-7111